Biote Reports Q1 2026 Earnings with Revenue Decline and Recall Impact
Biote (BTMD) reported Q1 2026 earnings with $44.9 million in revenue, an 8.3% decrease, primarily due to a voluntary recall of hormone pellets. Procedure revenue dropped 13.2% to $31.3 million, while dietary supplement revenue rose 19.1% to $11 million. Gross profit margin fell to 68.9% from 74.3%, and net income dropped to $2.7 million from $15.8 million.
Topics: adjusted_ebitda earnings profit recall revenue